AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
CANTON, Mass., May 02, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
